Risankizumab Tops Ustekinumab on Complete Clearance in Pediatric Psoriasis
In phase 3 OptIMMize-1 data published in the British Journal of Dermatology, risankizumab matched ustekinumab on most endpoints at week 16 but more than doubled the PASI-100 rate in adolescents aged…